Cardiff Oncology, Inc. · NASDAQ:CRDF
Cardiff Oncology — Corporate Update (September 2022)
66 slides from Cardiff Oncology's corporate update, Sep 12, 2022
Slide 1: Clinical and Corporate Update
Clinical and Corporate Update SEPTEMBER 12, 2022
Slide 2: Forward-looking statements
Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities uncertainties of government or third-party payer reimbursement; Litigation Reform Act of 1995. These statements may be identified by the dependence on key personnel; li
Slide 3: Many chemo agents damage a tumor cell's ability to replicate
Many chemo agents damage a tumor cell’s ability to replicate Irinotecan 5-FU DNA Further synthesis S G2 cell growth G1 M Initial Mitosis cell growth (cell division) Taxanes 3
Slide 4: Cancers thrive because they prioritize DNA replication and cell division
Cancers thrive because they prioritize DNA replication and cell division 4
Slide 5: PLK1 is a master regulator of genome integrity during cell replication
PLK1 is a master regulator of genome integrity during cell replication DNA Further synthesis S G2 cell growth G1 M Initial Mitosis cell growth (cell division) 5
Slide 6: PLK1 is a master regulator of genome integrity during cell replication
PLK1 is a master regulator of genome integrity during cell replication PLK1 plays multiple roles DNA Further synthesis S G2 cell growth during cell cycle Controls the repair of S-Phase DNA damage G1 M G2/M Initial Mitosis Checkpoint cell growth (cell division) M-Phase 6
Slide 7: PLK1 is a master regulator of genome integrity during cell replication
PLK1 is a master regulator of genome integrity during cell replication PLK1 plays multiple roles DNA Further synthesis S G2 cell growth during cell cycle Controls the repair of PLK1 S-Phase DNA damage G1 M G2/M Controls the checkpoint Initial Mitosis Checkpoint for DNA quality cell growth (cell divi
Slide 8: PLK1 is a master regulator of genome integrity during cell replication
PLK1 is a master regulator of genome integrity during cell replication PLK1 plays multiple roles DNA Further synthesis S G2 cell growth during cell cycle Controls the repair of S-Phase DNA damage G1 M G2/M Controls the checkpoint Initial Mitosis Checkpoint for DNA quality cell growth (cell division)
Slide 9: Onvansertib inhibits PLK1
PLK1 is a master regulator of genome integrity during cell replication ONVANSERTIB INHIBITS PLK1 onvansertib shuts down PLK1’s cell- preservation mechanisms, enhancing the efficacy of cell- damaging cancer therapies 9
Slide 10: Onvansertib positions Cardiff Oncology to effectively target PLK1
Onvansertib positions Cardiff Oncology to effectively target PLK1 PROPERTIES SPECIFICITY • Small molecule Exquisitely specific for PLK1 • Oral dosing ENZYME IC50 (µM) • 24-hour half-life PLK1 0.002 PLK2 >10.000 PLK3 >10.000 CK2 0.400 FLT3 0.400 CDK1/CycB >10.000 42 other kinases >10.000 and >140 in
Slide 11: Two goals drive our near-term clinical development program
Two goals drive our near-term clinical development program 2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 GOALS 1 Validate prior mCRC data with a randomized trial 2 Demonstrate clinical POC in additional indications 11
Slide 12: Today we'll see where we are, and where we're going
Today we’ll see where we are, and where we’re going Accelerating our mCRC program Initial trial: phase 1b/2 Next trial Additional onvansertib programs 12
Slide 13: Today we'll see where we are, and where we're going
Today we’ll see where we are, and where we’re going Accelerating our mCRC program Pancreatic cancer (mPDAC) Prostate cancer (mCRPC) Additional onvansertib programs Triple negative breast cancer (TNBC) Small cell lung cancer (SCLC) 13
Slide 14: Accelerating our mCRC program
Accelerating our mCRC program Initial trial: phase 1b/2 Next trial Additional onvansertib programs 14
Slide 15: There are no targeted therapies available for KRAS/NRAS mutations
There are no targeted therapies available for KRAS/NRAS mutations Normal 1st LINE 2nd LINE Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab Mutated mCRC is approx. half the mCRC population1 Targeted + EGFR inhibitor NONE Mutated Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab KRAS/NRAS Target
Slide 16: The prognosis for second-line mCRC patients is poor
The prognosis for second-line mCRC patients is poor Normal 1st LINE 2nd LINE HISTORICAL * Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab ORR Targeted + EGFR inhibitor NONE 5% 2006 – 2008 Mutated 11.4% 2000 – 2013 Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab Targeted NONE NONE 13% 2015 –
Slide 17: Adding onvansertib to SoC could address the unmet need
Adding onvansertib to SoC could address the unmet need Normal 1st LINE 2nd LINE Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab Targeted + EGFR inhibitor NONE Mutated Standard FOLFOX + bevacizumab FOLFIRI + bevacizumab Onvansertib has the Targeted NONE ONVANSERTIB potential to fill this gap 17
Slide 18: Gaps in KRAS-mutated mCRC therapies leave a significant unmet need
Gaps in KRAS-mutated mCRC therapies leave a significant unmet need KRAS/NRAS Mutations in mCRC1 Investigational therapies 3.8% G12C (Amgen; Mirati) address G12D the G12C KRAS mutation only G12V Normal G13D G12S G12A Q61H NRAS G13C 1. Jones R et al. Br J Cancer. 2017 Mar 28;116(7):923-929 18
Slide 19: Gaps in KRAS-mutated mCRC therapies leave a significant unmet need
Gaps in KRAS-mutated mCRC therapies leave a significant unmet need KRAS/NRAS Mutations in mCRC1 93% G12C G12D of patients with KRAS/NRAS mutations G12V miss targeted therapy Normal G13D G12S G12A Q61H NRAS G13C 1. Jones R et al. Br J Cancer. 2017 Mar 28;116(7):923-929 19
Slide 20: Onvansertib is positioned to address gaps in KRAS-mutated mCRC
Onvansertib is positioned to address gaps in KRAS-mutated mCRC KRAS/NRAS Mutations in mCRC1 G12C G12D MOA 1 Synthetic lethality in KRAS mutants 2 In KRAS-mutated mCRC, onversertib has two Synergy with G12V mechanisms of action 2nd-line SoC Normal G13D G12S G12A Q61H NRAS G13C 1. Jones R et al. Br J
Slide 21: Our Ph1/2b trial combined onvansertib with the current SoC
Our Ph1/2b trial combined onvansertib with the current SoC ENROLLMENT CRITERIA O N VA N S E R T I B 28 27 2nd line mCRC 26 KRAS+ 25 2nd-Line SoC: SINGLE ARM TRIAL Unresectable 24 FOLFIRI + bevacizumab 6 N=50 (48 evaluable) 23 7 Can we get a signal that 22 28 DAY CYCLE 8 onvansertib complements and i
Slide 22: Our Ph1/2b trial assessed safety, efficacy and response biomarker
Our Ph1/2b trial assessed safety, efficacy and response biomarker ENROLLMENT CRITERIA O N VA N S E R T I B 28 27 2nd line mCRC 26 KRAS+ 25 2nd-Line SoC: EFFICACY SINGLE ENDPOINTS ARM TRIAL Unresectable 24 FOLFIRI + bevacizumab 6 N=50 (48 evaluable) 23 7 Can we get a signal that Primary: Objective Re
Slide 23: Patients achieved a strong, durable response with onvansertib + SoC
Patients achieved a strong, durable response with onvansertib + SoC Best Radiographic Response* – all doses (as of July 25, 2022) All Doses RP2D % change in target lesions from baseline Objective Response Rate* 35% (17/48) 34% (12/35) (CR + PR) Disease Control Rate 92% (44/48) 94% (33/35) (CR + PR +
Slide 24: We observe initial PRs up to eight months on treatment
We observe initial PRs up to eight months on treatment Swimmer plot* – all doses (as of July 25, 2022) Evaluable Patients – all doses 48 Time of initial PR On Trial On Follow Up 8-week scan 8 16-week scan 3 24-week scan 5 32-week scan 1 * Swimmer plot and table reflect interim data as of July 25, 20
Slide 25: Patients achieved responses across several KRAS mutations
Patients achieved responses across several KRAS mutations Swimmer plot* – all doses (as of July 25, 2022) Frequency of Common KRAS Onvansertib responses across KRAS mutations Mutations in mCRC1 (as of July 25, 2022) G12C KRAS G12D Evaluable Patients – all doses 48 Variant CR+PR SD PD Total G12D 6Tim
Slide 26: Objective Response Rate for mCRC trial exceeds SoC over time
Objective Response Rate for mCRC trial exceeds SoC over time Onvansertib+SoC ORR† over time RP2D 42% 8 of 19 ALL DOSES 36% ALL DOSES 38% ALL DOSES 35% 17 of 48 12 of 32 Historical SoC* ORR 5 of 14 34% RP2D 12 of 35 11.4% 13% 5% 2008 ‘13 ‘17 Jan Apr Jul Oct Jan 2021 2022 * 2008: Bennouna et al., Lanc
Slide 27: Progression Free Survival for mCRC trial exceeds SoC over time
Progression Free Survival for mCRC trial exceeds SoC over time Progression free survival† – all doses (as of July 25, 2022) 1.00 Probability of Survival 0.75 Historical SoC* mPFS (mo) 5.7 5.6 4.5 0.50 0.25 2008 2013 2017 0.00 Median PFS: 9.3 0 5 10 15 20 Months * 2008: Bennouna et al., Lancet Oncol
Slide 28: Progression Free Survival for mCRC trial exceeds SoC over time
Progression Free Survival for mCRC trial exceeds SoC over time Onvansertib+SoC mPFS† ALL DOSES Historical SoC* mPFS (mo) 9.4 mo 9.4 mo 9.3 mo 5.6 8.2 mo 5.7 RP2D 4.5 Oct Jan Apr Jul Oct 2008 2013 2017 2021 2022 † Onvansertib mPFS are interim data from an ongoing trial and unlocked database * 2008: B
Slide 29: Onvansertib in combination with FOLFIRI-bev is well-tolerated
Onvansertib in combination with FOLFIRI-bev is well-tolerated GRADE GRADE No major/unexpected toxicities TEAEs* 1 2 3 4 All TEAEs* 1 2 3 4 All • Of all TEAEs, only 11% (84/788) Neutropenia 1 13 15 6 35 Anemia 9 4 1 0 14 were G3/G4 Fatigue 15 15 3 0 33 Vomiting 9 3 1 0 13 Musculoskeletal • 7 patients
Slide 30: The trial's patient demographics reflects 2nd line mCRC population
The trial’s patient demographics reflects 2nd line mCRC population Enrollment* Phase 1b, Dose Level 0 Phase 1b, Dose Level +1 Phase 1b, Dose Level +2 Phase 2 RP2D Total Patients Number of Patients (N) Onvansertib 12 mg/m2 Onvansertib 15 mg/m2 Onvansertib 18 mg/m2 Onvansertib 15 mg/m2 All Doses Treat
Slide 31: Anti-angiogenics, like bevacizumab, combine with 1st and 2nd line SoC
Anti-angiogenics, like bevacizumab, combine with 1st and 2nd line SoC 1st LINE 2nd LINE FOLFOX + FOLFIRI + Normal bevacizumab bevacizumab mCRC Ph1b/2 trial + EGFR inhibitor N=50 (48 evaluable) Do 2nd line patients naïve to bev show better efficacy than 2nd line patients with prior bev in 1st line? R
Slide 32: 1st line use of bev in prior trials has minimal impact on 2nd line efficacy
1st line use of bev in prior trials has minimal impact on 2nd line efficacy 2nd LINE EFFICACY DATA FROM HISTORICAL TRIALS IN mCRC BEV EXPOSURE IN 1ST LINE? FOLFIRI + 2nd Line ORR3-6 2nd Line mPFS (mo)1-2 2nd Line mOS (mo)1-2 Normal bevacizumab 13.9 12.5 RAS FOLFIRI + 6.9 6.7 Mutated bevacizumab 25%
Slide 33: Ph 1b/2 trial bev naïve patients had unexpectedly high ORR and mPFS
Ph 1b/2 trial bev naïve patients had unexpectedly high ORR and mPFS 2nd LINE HISTORICAL CONTROLS VS ONVANSERTIB* Ph 1b/2 DATA BEV EXPOSURE IN 1ST LINE? FOLFIRI + 2nd Line ORR3-6 2nd Line mPFS (mo)1-2 Normal bevacizumab 69% 13.5 7.8 RAS FOLFIRI + 6.9 6.7 bevacizumab Mutated 25% 23% + ONVANSERTIB 13%
Slide 34: ORR is consistently greater for bev naïve patients across characteristics
ORR is consistently greater for bev naïve patients across characteristics No single patient ORR (%) for Bevacizumab Naïve vs. Exposed Patients* characteristic explains 80% 80% 80% observed ORR difference 75% 71% 70% 69% 67% 67% 67% 63% 60% 56% 50% BEV EXPOSURE IN 1ST LINE? No Yes 31% 27% 26% (naïve)
Slide 35: The potential onvansertib bevacizumab synergy is a new opportunity
The potential onvansertib bevacizumab synergy is a new opportunity How should we respond HYPOTHESES ACTIONS to this observation? 1. Stratify for prior bev exposure within A. This is a statistical randomization of next mCRC trial anomaly (small n)? B. This is due to onv / 2. Explore apparent onv / be
Slide 36: Early KRAS MAF ctDNA decrease correlates w/ radiographic response
Early KRAS MAF ctDNA decrease correlates w/ radiographic response % KRAS Mutant Allelic Frequency (MAF)* Predictive response biomarker decrease after one 28-day treatment cycle (Mean ±SD, as of July 25, 2022) • 45 of the 48 evaluable patients were evaluated for KRAS MAF changes 0 * % Change in KRAS
Slide 37: Early Changes in KRAS MAF predicts clinical response
Early Changes in KRAS MAF predicts clinical response ORR (%) mPFS (mo) 1.00 Probability of Survival KRAS RESPONDERS KRAS KRAS RESPONDERS RESPONDERS 0.75 64% 12.6 mo 14 of 22 KRAS NON-RESPONDERS 0.50 KRAS NON-RESPONDERS 6.0 mo 0.25 KRAS NON-RESPONDERS 0.00 6.0 12.6 P = 0.019 9% 2 of 23 0 5 10 15 20 M
Slide 38: Accelerating our mCRC program
Accelerating our mCRC program Initial trial: phase 1b/2 Next trial Additional onvansertib programs 38
Slide 39: We believe that onvansertib complements and improves SoC
We believe that onvansertib complements and improves SoC Our Ph1b/2 Question: Can we get a signal that Historical SoC* ORR Ph1b/2 ORR onvansertib complements and improves SoC? 35% ALL DOSES 34% RP2D 11.4% 13% 5% 2008 ‘13 ‘17 2022 * Bennouna et al., Lancet Oncol 2013; 14: 29–37; Giessen et al., Acta
Slide 40: We approach our next trial with four clear objectives
We approach our next trial with four clear objectives DEMONSTRATE onvansertib’s contribution to SoC CONFIRM optimal dosing POSITION for possible accelerated approval opportunity OPERATE with capital efficiency 40
Slide 41: Our ONSEMBLE Ph2 trial is designed to demonstrate efficacy
Our ONSEMBLE Ph2 trial is designed to demonstrate efficacy ENROLLMENT CRITERIA O N VA N S E R T I B 28 SoC (FOLFIRI + Bev) 27 2nd line mCRC R 26 KRAS+/NRAS+ SoC + onvansertib (20mg) 25 N=150 2nd-Line SoC: 24 6 Unresectable 1:1:1 FOLFIRI + bevacizumab SoC + onvansertib (30mg) 23 7 22 28 DAY CYCLE 8 2
Slide 42: Our ONSEMBLE Ph2 trial is designed to demonstrate efficacy
Our ONSEMBLE Ph2 trial is designed to demonstrate efficacy ENROLLMENT CRITERIA ENDPOINTS 2nd line mCRC Primary Objective Response Rate: CR + PR KRAS+/NRAS+ R N=150 Key Secondary Progression-Free Survival Unresectable 1:1:1 Other Secondary Disease Control Rate: CR + PR + SD Duration of Response: DoR
Slide 43: Our ONSEMBLE Ph2 trial will be statistically robust
Our ONSEMBLE Ph2 trial will be statistically robust ENROLLMENT CRITERIA 2nd line mCRC DESIGN • Randomized with control group exclusively the SoC KRAS+/NRAS+ R N=150 • Examine two doses of onvansertib for safety/efficacy Unresectable 1:1:1 • Stratification within randomization for bev-naïve vs bev ex
Slide 44: We are optimistic that randomized data will create substantial value
We are optimistic that randomized data will create substantial value 2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Trial mCRC activation randomized data readout Opportunity to • Rigorous demonstration of onvansertib’s role in increasing create value efficacy in mCRC vs. SoC alone • Position for
Slide 45: Additional onvansertib programs
Accelerating our mCRC program Pancreatic cancer (mPDAC) Prostate cancer (mCRPC) Additional onvansertib programs Triple negative breast cancer (TNBC) Small cell lung cancer (SCLC) 45
Slide 46: Our mPDAC Ph2 trial combines onvansertib with standard-of-care
Our mPDAC Ph2 trial combines onvansertib with standard-of-care ENROLLMENT CRITERIA O N VA N S E R T I B 14 Failed 1st Line Gemcitabine / Abraxane 13 SINGLE ARM TRIAL 2nd-Line SoC: Nal-IRI 43 patients planned + Leucovorin + 5-FU 12 Can we get a signal that onvansertib complements and improves SoC? 11
Slide 47: The endpoints measure tumor response and duration of response
The endpoints measure tumor response and duration of response ENROLLMENT CRITERIA O N VA N S E R T I B 14 Failed 1st Line Gemcitabine / Abraxane EFFICACY SINGLE ARM TRIAL 13 2nd-Line SoC: Nal-IRI ENDPOINTS N=6/43 + Leucovorin + 5-FU 12 Here’s Primary: Objective what we’re Response Ratetrying (ORR) i
Slide 48: mPDAC trial is designed to demonstrate onvansertib's efficacy vs SoC
mPDAC trial is designed to demonstrate onvansertib’s efficacy vs SoC ENROLLMENT CRITERIA O N VA N S E R T I B 14 Failed 1st Line Gemcitabine HISTORICAL / Abraxane RESPONSE RATE* 13 SINGLE ARM PROOF OF CONCEPT TRIAL CRITERIA 2nd-Line SoC: Nal-IRI N=6/43 + Leucovorin + 5-FU 7.7% ORR Here’s what we’re
Slide 49: Early data from our mPDAC trial data is encouraging
Early data from our mPDAC trial data is encouraging Swimmer plot* – as of August 30, 2022 Change in tumor size from baseline* % Change in Target Lesions 04-012 20 2 4 6 Months 0 04-008 05-014 05-009 0 2.5 5.0 7.5 Months -20 02-011 -40 * Swimmer and spider plots reflect interim data as of August 30,
Slide 50: Additional onvansertib programs
Accelerating our mCRC program Pancreatic cancer (mPDAC) Prostate cancer (mCRPC) Additional onvansertib programs Triple negative breast cancer (TNBC) Small cell lung cancer (SCLC) 50
Slide 51: AACR data showed disease control increased with dose density
AACR data showed disease control increased with dose density Evaluated onvansertib + abiraterone / prednisone in mCRPC patients showing initial abiraterone resistance by rising PSA Disease control increased with onvansertib dose density • From 29% to 45% of patients achieving PSA stabilization, and
Slide 52: We are not planning to fund any future mCRPC development activity
We are not planning to fund any future mCRPC development activity FINDINGS PATH FORWARD The trial completed enrollment (n=72) and Cardiff Oncology is not planning for any company- generated important clinical data: sponsored future steps in mCRPC • Negligible toxicities attributed to onvansertib • D
Slide 53: Additional onvansertib programs
Accelerating our mCRC program Pancreatic cancer (mPDAC) Prostate cancer (mCRPC) Additional onvansertib programs Triple negative breast cancer (TNBC) Small cell lung cancer (SCLC) 53
Slide 54: Onvansertib + paclitaxel is superior to single agent therapy
Onvansertib + paclitaxel is superior to single agent therapy TRIAL RATIONALE In vivo efficacy of onvansertib in combination with paclitaxel Tp53-Mutant SUM159 xenografts* The combination of onvansertib + paclitaxel 1200 Tumor volume (mm3) showed significant synergy 1000 control (n=8) 800 paclitaxel
Slide 55: This is the first trial to explore onvansertib + paclitaxel combination
This is the first trial to explore onvansertib + paclitaxel combination ENROLLMENT CRITERIA PRIMARY ENDPOINTS O N VA N S E R T I B 28 Start: 9 mg/m2 Metastatic TNBC relapsed Phase 1b 27 26 or progressed Safety, characterization 25 of DLTs Paclitaxel Single arm trial Determination of RP2D 24 80 mg/m2
Slide 56: This is the first trial to explore onvansertib + paclitaxel combination
This is the first trial to explore onvansertib + paclitaxel combination ENROLLMENT CRITERIA PRIMARY ENDPOINTS O N VA N S E R T I B 28 RP2D Metastatic TNBC relapsed Phase 1b 27 26 or progressed Safety, characterization 25 of DLTs Paclitaxel Single arm trial Determination of RP2D 24 80 mg/m2 Ph 1b: N=
Slide 57: Additional onvansertib programs
Accelerating our mCRC program Pancreatic cancer (mPDAC) Prostate cancer (mCRPC) Additional onvansertib programs Triple negative breast cancer (TNBC) Small cell lung cancer (SCLC) 57
Slide 58: Onvansertib demonstrates single-agent activity in SCLC
Onvansertib demonstrates single-agent activity in SCLC TRIAL RATIONALE In vivo efficacy of onvansertib monotherapy (SCLC xenografts)* Onvansertib monotherapy CISPLATIN RESISTANT CISPLATIN SENSIVITVE showed significant tumor 2000 2000 Tumor volume (mm3) growth inhibition against con. platinum-sensiti
Slide 59: This is the first trial to explore onvansertib monotherapy
This is the first trial to explore onvansertib monotherapy O N VA N S E R T I B ENROLLMENT CRITERIA PRIMARY ENDPOINT Relapsed who have Phase 2 21 received ≤ 2 prior therapies ORR (RECIST 1.1) 20 onvansertib 19 Single-arm trial monotherapy Stage 1: N=15 18 15 mg/m2 Stage 2: N=20 SECONDARY ENDPOINTS 1
Slide 60: Our pipeline opens many attractive opportunities for onvansertib
Our pipeline opens many attractive opportunities for onvansertib Combination with: Preclinical Ph1/2 Ph2/3 Status mCRC FOLFIRI/bev Activation randomized mCRC FOLFIRI/bev Enrolling single-arm mPDAC Onivyde/5-FU Enrolling Ovarian PARP inhibitors Evaluating Investigator-initiated trials Investigator TN
Slide 61: Targeting PLK1 opens doors to large patient populations
Targeting PLK1 opens doors to large patient populations Annual eligible US patients (’000s)* Targets with Targets without oncogenic oncogenic ONVANSERTIB alterations alterations 40 39 ROS1 PLK1 RET PARP 30 23 KRAS G12C CDK4/6 20 EGFR PD1/PDL1 15 12 TRK VEGF 10 3 5 0 * ROS1 estimated eligible patient
Slide 62: We have multiple important catalysts over the next two years
We have multiple important catalysts over the next two years 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 mPDAC TNBC mCRC data readout data readout randomized 39 data readout SCLC data readout 23 15 12 mCRC mPDAC TNBC SCLC 2L K/N-mut 2L 2L invasive Salvage 62
Slide 63: At June 30, 2022, our financial position is robust
At June 30, 2022, our financial position is robust 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 mPDAC TNBC mCRC data readout data readout randomized data readout SCLC data readout June 30, 2022 cash and investments* $122.0M Net cash used in Operating Activities* $16.9M (Rolling two-quarter period en
Slide 64: Our clinical development program supports our key goals
Our clinical development program supports our key goals 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 GOALS 1 Validate prior mCRC data with a randomized trial 2 Demonstrate clinical POC in additional indications 64
Slide 65: Our clinical development program supports our key goals
Our clinical development program supports our key goals 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 GOALS OUR STRATEGY Phase 1b/2 single arm Phase 2 randomized 1 Validate prior mCRC data with a randomized trial Strong ORR + DoR + PFS MAF biomarker opportunity Efficient design Confirm dose; stratify
Slide 66: Q&A
Q&A 66